ArticleBlood cancer journal2015

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.

T Narita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.